The FDA has approved Dupixent for the treatment of patients aged 12 years and older with CSU who remain symptomatic despite H1 antihistamine treatment.

Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification ...

The FDA approved dupilumab for the treatment of patients 12 years and older with chronic spontaneous urticaria who remain ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adults and adolescents with ...

Marking the first approval in over a decade for this challenging condition, the FDA has approved dupilumab (Dupixent) to ...

This could include allergy testing, blood tests to detect inflammation markers, or tests for celiac disease or thyroid problems. If the hives are not always apparent, it may help for a person to ...

Dupixent, which was rejected by the FDA for chronic spontaneous urticaria in October 2023, is now approved as the first new ...

The partners overcame an earlier rejection to win a seventh use for Dupixent, though some analysts are skeptical of its sales ...

Resubmission of the supplemental biologics license application provided more data on improvement in hives and itching in ...